Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
REVENUES
COST AND EXPENSES
Research and Development	22,969	8,042	25,206	13,867
General and Administrative	336,286	139,251	494,730	326,436
Consulting and Professional Fees	303,666	37,509	386,195	108,003
Rent	15,000		26,871
Total Costs and Expenses	677,922	184,802	933,003	448,306
OPERATING LOSS	(677,922)	(184,802)	(933,003)	(448,306)
OTHER INCOME & (EXPENSES)
Interest Income	291		551
Interest Expense	(18,694)	(8,523)	(33,265)	(17,407)
Loss on Settlement of Debt through Equity Issuance	(249,030)	(336,230)	(836,530)	(984,730)
Loss on Settlement of Debt through Issuance of Common Shares of Regen biopharma, Inc. below fair value	(8,179,432)		(8,179,432)
Interest Expense attributable to amortization of discount	(4,032)		(4,032)
Expense Related to issuance of Convertible Debt to Star City	(247,500)		(247,500)
Preferred Shares of Regen Biopharma, Inc. issued pursuant to contractual obligations	(3,154)		(3,154)
Total Other Income & (Expense)	(8,701,551)	(344,753)	(9,303,362)	(1,002,137)
NET INCOME (LOSS) before loss attributable to noncontrolling interest in Entest Biomedical, Inc. and equity in subsidiary losses	(9,379,473)	(529,555)	(10,236,365)	(1,450,443)
(Net Income) Loss attributable to noncontrolling interest in Entest Biomedical, Inc.	0	0	0	0
NET INCOME (LOSS) before equity in subsidiary losses	(9,379,473)	(529,555)	(10,236,365)	(1,450,443)
Equity in Net Income (Loss) of Entest Biomedical, Inc.	0	0	0	0
NET INCOME (LOSS)	(9,379,473)	(529,555)	(10,236,365)	(1,450,443)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	7,117,519	71,738	7,212,122	78,539
NET INCOME (LOSS) available to common shareholders	$ (2,261,954)	$ (457,817)	$ (3,024,243)	$ (1,371,904)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0007)	$ (0.0002)	$ (0.0008)	$ (0.0005)
Weighted average number of shares outstanding	3,172,885,208	2,916,286,718	3,663,947,530	2,737,817,974